ABSTRACT
Objective To investigate characteristics and risk factors of a novel parenchymal lung disease, increasingly detected in systemic juvenile idiopathic arthritis (sJIA).
Methods In a multi-center retrospective study, 61 cases were investigated, using physician-reported clinical information and centralized analyses of radiologic, pathologic and genetic data.
Results Lung disease (LD) was associated with distinctive features, including acute erythematous clubbing and a high frequency of anaphylactic reactions to the IL-6 inhibitor, tocilizumab. Serum ferritin elevation and/or significant lymphopenia preceded LD detection. The most prevalent chest CT pattern was septal thickening, involving the periphery of multiple lobes +/- ground glass opacities. Predominant pathology (23/36) was pulmonary alveolar proteinosis and/or endogenous lipoid pneumonia (PAP/ELP), with atypical features, including regional involvement and concomitant vascular changes. Apparent severe delayed drug hypersensitivity occurred in some cases. 5-year survival was 42%. Whole-exome sequencing (20/61) did not identify a novel monogenic defect PAP-related or macrophage activation syndrome (MAS)-related mutations as likely primary cause. Trisomy 21 (T21) increased LD risk, as did young sJIA onset. Refractory sJIA was not required for LD development. Exposure to interleukin (IL)-1 and IL-6 inhibitors (46/61) was associated with multiple LD features. By several indicators, severity of sJIA was comparable in drug-exposed subjects and published sJIA cohorts. MAS at sJIA onset was increased in the drug-exposed, but it was not associated with LD features.
Conclusions A rare, life-threatening LD in sJIA is defined by a constellation of unusual clinical characteristics. The pathology, a PAP/ELP variant, suggests macrophage dysfunction. Inhibitor exposure may promote LD, independent of sJIA severity, in a small subset of treated patients. Treatment/prevention strategies are needed.
Competing Interest Statement
All the following competing interests are outside the submitted work. Dr. Mellins reports a research grant from Novartis. Dr. Shenoi reports personal fees from Novartis. Dr. Canna reports personal fees from Novartis, grants from AB2Bio, Ltd. Dr. Stoll reports personal fees from Novartis. Dr. Grom reports grants and personal fees from Novartis, grants from NovImmune.Dr. Deutsch reports personal fees from Novartis.Dr. Saper reports personal fees from Novartis.Dr. Schneider reports personal fees from Novartis, Novimmune and SOBI; Dr. Young reports other from Up To Date, other from Boehringer Ingelheim; Dr. Baszis reports personal fees from Novartis.
Funding Statement
This work was supported by the sJIA Foundation (EDM), the Lucile Packard Foundation for Children's Health (EDM), CARRA-Arthritis Foundation grant (EDM, VS), Life Sciences Research Foundation (GC), Bio-X Stanford Interdisciplinary Graduate Fellowship (JB), Stanford Graduate Fellowship and the Computational Evolutionary Human Genetics Fellowship (KJ). NIH (LRY); Bill & Melinda Gates Foundation (PK), NIH: 1U19AI109662 (PK), U19AI057229 (PK), RO1 AI125197 (PK).
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Not Applicable
Data Availability
Data are available upon reasonable request.
